Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma

被引：14

作者：

Glen, Hilary ^{[1
]}

机构：

[1] Beatson West Scotland Canc Ctr, Dept Med Oncol, 1053 Great Western Rd, Glasgow G12 OYN, Lanark, Scotland

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 19期

关键词：

everolimus; FGFR; lenvatinib; mTOR; renal cell carcinoma; VEGFR; TYROSINE KINASE INHIBITOR; PHASE-III TRIAL; COMBINATION TARGETED THERAPY; ENDOTHELIAL GROWTH-FACTOR; INTERFERON-ALPHA; DOVITINIB TKI258; FACTOR RECEPTORS; DOUBLE-BLIND; EVEROLIMUS; BEVACIZUMAB;

D O I：

10.2217/fon-2016-0215

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite advances in metastatic renal cell carcinoma (mRCC) treatments, patients eventually progress and develop resistance to therapies targeting a single pathway. Lenvatinib inhibits VEGFR1-3, FGFR1-4, PDGFR beta, RET and KIT proto-oncogenes. In a randomized, Phase II trial evaluating patients with mRCC who had progressed after one prior VEGF-targeted therapy, progression-free survival was significantly improved with lenvatinib alone or in combination with everolimus versus everolimus alone. This review summarizes the clinical development of lenvatinib in mRCC, and how simultaneous targeting of multiple pathways involved in carcinogenesis and/ or therapeutic resistance may improve patient outcomes. Lenvatinib plus everolimus may be a promising second-line treatment in patients with mRCC.

引用

页码：2195 / 2204

页数：10

共 53 条

[1] Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma [J].

Angevin, Eric ;

Lopez-Martin, Jose A. ;

Lin, Chia-Chi ;

Gschwend, Juergen E. ;

Harzstark, Andrea ;

Castellano, Daniel ;

Soria, Jean-Charles ;

Sen, Paramita ;

Chang, Julie ;

Shi, Michael ;

Kay, Andrea ;

Escudier, Bernard .

CLINICAL CANCER RESEARCH, 2013, 19 (05) :1257-1268

[2]

[Anonymous], 2014, GUIDELINES RENAL CEL

[3]

[Anonymous], 2015, LENVIMA LENVATINIB P

[4] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[5] A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours [J].

Boss, D. S. ;

Glen, H. ;

Beijnen, J. H. ;

Keesen, M. ;

Morrison, R. ;

Tait, B. ;

Copalu, W. ;

Mazur, A. ;

Wanders, J. ;

O'Brien, J. P. ;

Schellens, J. H. M. ;

Evans, T. R. J. .

BRITISH JOURNAL OF CANCER, 2012, 106 (10) :1598-1604

[6]

Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154

[7]

Cancer Research UK, KIDN CANC INC STAT

[8] Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J].

Casanovas, O ;

Hicklin, DJ ;

Bergers, G ;

Hanahan, D .

CANCER CELL, 2005, 8 (04) :299-309

[9] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Escudier, B. ;

Powles, T. ;

Mainwaring, P. N. ;

Rini, B. I. ;

Donskov, F. ;

Hammers, H. ;

Hutson, T. E. ;

Lee, J-L ;

Peltola, K. ;

Roth, B. J. ;

Bjarnason, G. A. ;

Geczi, L. ;

Keam, B. ;

Maroto, P. ;

Heng, D. Y. C. ;

Schmidinger, M. ;

Kantoff, P. W. ;

Borgman-Hagey, A. ;

Hessel, C. ;

Scheffold, C. ;

Schwab, G. M. ;

Tannir, N. M. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823

[10] Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical Applicability [J].

Eichelberg, Christian ;

Junker, Kerstin ;

Ljungberg, Borje ;

Moch, Holger .

EUROPEAN UROLOGY, 2009, 55 (04) :851-863

← 1 2 3 4 5 6 →